Ning Ding1, Chao Yang1, Shoshana H Ballew1, Corey A Kalbaugh2, John W McEvoy1,3, Maya Salameh1, David Aguilar4, Ron C Hoogeveen5, Vijay Nambi6, Elizabeth Selvin1, Aaron R Folsom7, Gerardo Heiss8, Josef Coresh1, Christie M Ballantyne5, Kunihiro Matsushita1. 1. From the Johns Hopkins University, Baltimore, MD (N.D., C.Y., S.H.B., J.W.M., M.S., E.S., J.C., K.M.). 2. Department of Public Health Sciences at Clemson University (C.A.K.). 3. National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway (J.W.M.). 4. University of Texas Health Science Center, Houston (D.A.). 5. Baylor College of Medicine, Houston, TX (R.C.H., C.M.B.). 6. Michael E. DeBakey Veterans Affairs Hospital and Baylor College of Medicine, Houston, TX (V.N.). 7. School of Public Health, University of Minnesota, Minneapolis (A.R.F.). 8. Gillings School of Global Public Health, University of North Carolina, Chapel Hill (G.H.).
Abstract
OBJECTIVE: Inflammatory markers, such as hs-CRP (high-sensitivity C-reactive protein), have been reported to be related to peripheral artery disease (PAD). Galectin-3, a biomarker of fibrosis, has been linked to vascular remodeling and atherogenesis. However, its prospective association with incident PAD is unknown; as is the influence of inflammation on the association between galectin-3 and PAD. Approach and Results: In 9851 Atherosclerosis Risk in Communities Study participants free of PAD at baseline (1996-1998), we quantified the association of galactin-3 and hs-CRP with incident PAD (hospitalizations with PAD diagnosis [International Classification of Diseases-Ninth Revision: 440.2-440.4] or leg revascularization [eg, International Classification of Diseases-Ninth Revision: 38.18]) as well as its severe form, critical limb ischemia (PAD cases with resting pain, ulcer, gangrene, or leg amputation) using Cox models. Over a median follow-up of 17.4 years, there were 316 cases of PAD including 119 critical limb ischemia cases. Log-transformed galectin-3 was associated with incident PAD (adjusted hazard ratio, 1.17 [1.05-1.31] per 1 SD increment) and critical limb ischemia (1.25 [1.05-1.49] per 1 SD increment). The association was slightly attenuated after further adjusting for hs-CRP (1.14 [1.02-1.27] and 1.22 [1.02-1.45], respectively). Log-transformed hs-CRP demonstrated robust associations with PAD and critical limb ischemia even after adjusting for galectin-3 (adjusted hazard ratio per 1 SD increment 1.34 [1.18-1.52] and 1.34 [1.09-1.65], respectively). The addition of galectin-3 and hs-CRP to traditional atherosclerotic predictors (C statistic of the base model 0.843 [0.815-0.871]) improved the risk prediction of PAD (ΔC statistics, 0.011 [0.002-0.020]). CONCLUSIONS: Galectin-3 and hs-CRP were independently associated with incident PAD in the general population, supporting the involvement of fibrosis and inflammation in the pathophysiology of PAD.
OBJECTIVE: Inflammatory markers, such as hs-CRP (high-sensitivity C-reactive protein), have been reported to be related to peripheral artery disease (PAD). Galectin-3, a biomarker of fibrosis, has been linked to vascular remodeling and atherogenesis. However, its prospective association with incident PAD is unknown; as is the influence of inflammation on the association between galectin-3 and PAD. Approach and Results: In 9851 Atherosclerosis Risk in Communities Study participants free of PAD at baseline (1996-1998), we quantified the association of galactin-3 and hs-CRP with incident PAD (hospitalizations with PAD diagnosis [International Classification of Diseases-Ninth Revision: 440.2-440.4] or leg revascularization [eg, International Classification of Diseases-Ninth Revision: 38.18]) as well as its severe form, critical limb ischemia (PAD cases with resting pain, ulcer, gangrene, or leg amputation) using Cox models. Over a median follow-up of 17.4 years, there were 316 cases of PAD including 119 critical limb ischemia cases. Log-transformed galectin-3 was associated with incident PAD (adjusted hazard ratio, 1.17 [1.05-1.31] per 1 SD increment) and critical limb ischemia (1.25 [1.05-1.49] per 1 SD increment). The association was slightly attenuated after further adjusting for hs-CRP (1.14 [1.02-1.27] and 1.22 [1.02-1.45], respectively). Log-transformed hs-CRP demonstrated robust associations with PAD and critical limb ischemia even after adjusting for galectin-3 (adjusted hazard ratio per 1 SD increment 1.34 [1.18-1.52] and 1.34 [1.09-1.65], respectively). The addition of galectin-3 and hs-CRP to traditional atherosclerotic predictors (C statistic of the base model 0.843 [0.815-0.871]) improved the risk prediction of PAD (ΔC statistics, 0.011 [0.002-0.020]). CONCLUSIONS:Galectin-3 and hs-CRP were independently associated with incident PAD in the general population, supporting the involvement of fibrosis and inflammation in the pathophysiology of PAD.
Authors: Aruna D Pradhan; Sanjay Shrivastava; Nancy R Cook; Nader Rifai; Mark A Creager; Paul M Ridker Journal: Circulation Date: 2008-01-28 Impact factor: 29.690
Authors: Michael S Conte; Frank B Pomposelli; Daniel G Clair; Patrick J Geraghty; James F McKinsey; Joseph L Mills; Gregory L Moneta; M Hassan Murad; Richard J Powell; Amy B Reed; Andres Schanzer; Anton N Sidawy Journal: J Vasc Surg Date: 2015-01-28 Impact factor: 4.268
Authors: Ioanna Tzoulaki; Gordon D Murray; Amanda J Lee; Ann Rumley; Gordon D O Lowe; F Gerald R Fowkes Journal: Eur Heart J Date: 2007-01-09 Impact factor: 29.983
Authors: Jing Chen; Emile R Mohler; Dawei Xie; Michael Shlipak; Raymond R Townsend; Lawrence J Appel; Akinlolu Ojo; Martin Schreiber; Lisa Nessel; Xiaoming Zhang; Dominic Raj; Louise Strauss; Claudia M Lora; Mahboob Rahman; L Lee Hamm; Jiang He Journal: Nephrol Dial Transplant Date: 2015-12-18 Impact factor: 5.992
Authors: Oluwaseun E Fashanu; Faye L Norby; David Aguilar; Christie M Ballantyne; Ron C Hoogeveen; Lin Y Chen; Elsayed Z Soliman; Alvaro Alonso; Aaron R Folsom Journal: Am Heart J Date: 2017-07-08 Impact factor: 4.749
Authors: Julio Madrigal-Matute; Jes Sandal Lindholt; Carlos Ernesto Fernandez-Garcia; Alberto Benito-Martin; Elena Burillo; Guillermo Zalba; Oscar Beloqui; Patricia Llamas-Granda; Alberto Ortiz; Jesus Egido; Luis Miguel Blanco-Colio; Jose Luis Martin-Ventura Journal: J Am Heart Assoc Date: 2014-08-05 Impact factor: 5.501
Authors: Sunnia T Chen; Leylah Azali; Seema A Bhat; Daniel Addison; Lindsay Rosen; Qiuhong Zhao; Tracy Wiczer; Marilly Palettas; John Gambril; Onaopepo Kola-Kehinde; Patrick Ruz; Sujay Kalathoor; Kerry Rogers; Adam Kittai; Michael Grever; Farrukh Awan; John C Byrd; Jennifer Woyach Journal: J Hematol Oncol Date: 2022-07-14 Impact factor: 23.168
Authors: Zachary R Salyers; Vinicius Mariani; Nicholas Balestrieri; Ravi A Kumar; Nicholas A Vugman; Trace Thome; Katelyn R Villani; Scott A Berceli; Salvatore T Scali; Georgios Vasilakos; Terence E Ryan Journal: JVS Vasc Sci Date: 2022-04-21